Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03659448 · ClinicalTrials.gov registry record · Phase 3
Performance of SGM-101 for the Delineation of Primary and Recurrent Tumor and Metastases in Patients Undergoing Surgery for Colorectal Cancer
A Phase 3 study of Colorectal Neoplasms, sponsored by Surgimab.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 300
- Enrollment target
- 11
- Study locations
NCT03659448: Recruiting Phase 3 study of Colorectal Neoplasms, sponsored by Surgimab.
NCT03659448 is a Phase 3 study of Colorectal Neoplasms that is actively recruiting participants, run by Surgimab. The registered enrollment target is 300 participants, below the 571-participant average among 54 other Colorectal Neoplasms trials with a reported enrollment target (47% lower). The trial reports 11 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03659448, a Phase 3 study of Colorectal Neoplasms, is actively recruiting participants, sponsored by Surgimab.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 300 participants
- Enrollment target
- 11
- Study locations
Study Summary
The performance of SGM-101, an intraoperative imaging agent, will be compared to that of standard "white light" visualization during surgical resections of colorectal cancer.
Primary Outcome
Comparison of surgical resections using histopathology as standard of truth..
Conditions Studied
Interventions
- DRUG SGM-101
Study Locations (11)
Other
- Universitätsmedizin Göttingen, Klinik für Allgemein- Viszeral- und Kinderchirurgie - Göttingen
- Catharina Ziekenhuis Eindhoven - Eindhoven
- Leiden University Medical Center - Leiden
- Erasmus MC - Rotterdam
California
- City of Hope National Medical Center - Duarte
- Moores Cancer Center - UCSD Health - La Jolla
Massachusetts
- Massachusetts General Hospital - Boston
- University of Massachusetts - Worcester
Florida
- Cleveland Clinic Florida - Weston
Pennsylvania
- Perelman Center for Advanced Medicine - Philadelphia
Lombardy
- Fondazione IRCCS Policlinico San Matteo - Pavia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2019-06-17 |
| Est. Completion | 2024-12 |
| Phase | Phase 3 |
What NCT03659448 shows while recruiting
NCT03659448 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 571-participant average among 54 other Colorectal Neoplasms trials with a reported enrollment target (47% lower).
The record links to 1 condition, with Colorectal Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which SGM-101 is the first listed.
NCT03659448 lists 11 locations in 6 states (Other, California, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT03659448 about?
NCT03659448 is a clinical study titled "Performance of SGM-101 for the Delineation of Primary and Recurrent Tumor and Metastases in Patients Undergoing Surgery for Colorectal Cancer". The performance of SGM-101, an intraoperative imaging agent, will be compared to that of standard "white light" visualization during surgical resections of colorectal cancer.
What is the current status of trial NCT03659448?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 300 participants. The study started on 2019-06-17. Estimated completion is 2024-12.
What conditions does trial NCT03659448 study?
This clinical trial studies the following conditions: Colorectal Neoplasms.
What interventions are being tested in trial NCT03659448?
The interventions under investigation include: SGM-101 (DRUG).
Who is sponsoring clinical trial NCT03659448?
This trial is sponsored by Surgimab, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03659448 being conducted?
This trial has 11 study locations across California, Florida, Massachusetts, Pennsylvania, Lombardy. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03659448's enrollment target sits among peer trials
300 26th of 54 higher than 29 of 54 other Colorectal Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Colorectal Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
RECRUITING · Phase 3
-
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
RECRUITING · Phase 3
-
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
RECRUITING · Phase 3
-
S0820, Adenoma and Second Primary Prevention Trial
ACTIVE NOT RECRUITING · Phase 3
-
Trial Of Irinotecan In Combination With Three Methods Of Administration Of Fluoropyrimidine.
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI